Literature DB >> 2369739

Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells.

S Ozaki1, T Suginoshita, T Watanabe, H Obayashi.   

Abstract

OK-432, a streptococcal preparation, has been used in the treatment of malignant diseases. We have found that OK-432 can act as an antigen and have established an OK-432-specific L3T4+ Lyt2- T-cell line (OK2) and a clone (OK2.21) from OK-432-immunized BALB/c mice (Iad) as antitumor effector cells. OK2 proliferated and secreted interleukin 2, but only when OK-432 was presented by Iad-positive antigen-presenting cells. Despite its helper phenotype and function, OK2 could kill OK-432-pulsed Iad-positive B-lymphoma cells. This killing was inhibited only by cold specific target cells (cold-target inhibition). OK-432 induced the cytotoxicity of OK2 as a specific antigen, not as a nonspecific immunostimulator. OK2 and OK2.21 also killed Ia-negative bystander target cells only in the presence of OK-432-pulsed Iad-positive cells (bystander killing). Double-chamber experiments suggested that the bystander killing was mediated by a short-acting soluble cytolytic factor. Finally, the OK-432-specific T-cells selectively killed tumor cells, suggesting that these T-cells play an important role in the immune surveillance against malignancy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369739

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

Authors:  S Ozaki; T Okazaki; K Nakao
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

2.  Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.

Authors:  Y Katsumoto; T Monden; T Takeda; A Haba; Y Ito; E Wakasugi; T Wakasugi; M Sekimoto; T Kobayashi; H Shiozaki; T Shimano; M Monden
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

3.  Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.

Authors:  Y Yamaguchi; E Miyahara; A Ohshita; Y Kawabuchi; K Ohta; K Shimizu; K Minami; J Hihara; A Sawamura; T Toge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.